ScholarIQanswers from OpenAlex
Relypsa
FunderResearch funding and supported work
Relypsa is a funder indexed in ScholarIQ from OpenAlex.
What is known about Relypsa?
ScholarIQrecord summary
clinical trial
How many works does Relypsa have?
ScholarIQindexed works
Relypsa has 613 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Relypsa?
ScholarIQopenalex
The OpenAlex for Relypsa is on the source record.
What are the most-cited papers on Relypsa?
ScholarIQmost cited works
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Scott D. Solomon, John J.V. McMurray, Inder S. Anand, Junbo Ge, Carolyn S.P. Lam, Aldo P. Maggioni, Felipe A. Martínez, Milton Packer, Marc A. Pfeffer, Burkert Pieske, Margaret M. Redfield, Jean L. Rouleau, Dirk J. van Veldhuisen, Faı̈ez Zannad, Michael R. Zile, Akshay S. Desai, Brian Claggett, Pardeep S. Jhund, S. А. Boytsov, Josep Comín‐Colet, John G.F. Cleland, Hans‐Dirk Düngen, Eva Gonçalvesová, Tzvetana Katova, Jose F. Kerr Saraiva, Małgorzata Lelonek, Béla Merkely, Michele Senni, Sanjiv J. Shah, Jingmin Zhou, Adel R. Rizkala, Jianjian Gong, Victor Shi, Martin Lefkowitz
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial
Bertram Pitt, Stefan D. Anker, David A. Bushinsky, Dalane W. Kitzman, Faı̈ez Zannad, I‐Zu Huang, on behalf of the PEARL-HF Investigators
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos, Stefan D. Anker, Michael Böhm, Mihai Gheorghiade, Lars Køber, Henry Krum, Aldo P. Maggioni, Piotr Ponikowski, Adriaan A. Voors, Faı̈ez Zannad, So Young Kim, Christina Nowack, Giovanni Palombo, Peter Kolkhof, Nina Kimmeskamp‐Kirschbaum, Alexander Pieper, Bertram Pitt
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
Rajiv Agarwal, Patrick Rossignol, Alain Romero, Dahlia Garza, Martha Mayo, Suzette Warren, Jia Ma, William B. White, Bryan Williams
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
Pardeep S. Jhund, Scott D. Solomon, Kieran F. Docherty, Hiddo J.L. Heerspink, Inder S. Anand, Michael Böhm, Vijay Chopra, Rudolf A. de Boer, Akshay S. Desai, Junbo Ge, Masafumi Kitakaze, Bela Merkley, Eileen O’Meara, Morten Shou, С. Н. Терещенко, Subodh Verma, Pham Nguyễn Vinh, Silvio E. Inzucchi, Lars Køber, Mikhail Kosiborod, Felipe A. Martínez, Piotr Ponikowski, Marc S. Sabatine, Olof Bengtsson, Anna Maria Langkilde, Mikaela Sjöstrand, John J.V. McMurray